Cambridge, UK, 09 December 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation technologies, today announced the addition of predesigned synthetic single guide RNA (sgRNA) to its product range. The sgRNAs, available individually or as library collections, expand the Company’s Edit-R gene engineering platform which provides a convenient and accessible approach to successful CRISPR gene editing.Using synthetic sgRNAs enables researchers to achieve reliable gene knockouts in even complex,…
Westbury, NY – Dec. 9, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is hosting a drug discovery webinar that will discuss how small interfering RNA (siRNA) molecules can be used to selectively suppress hepatic genes in an in vitro liver model and advance the development of small molecule and nucleic acid therapies.
BioIVT’s HEPATOPAC® Technology is used to form a micro-patterned co-culture of primary hepatocytes and non-parenchymal stromal cells which maintain in vivo-like liver function and metabolic activity…
Cambridge, UK - 9 December 2019 - Healx the AI-powered biotechnology company focused on developing breakthrough treatments for rare diseases, today announces it has entered into an agreement with Boehringer Ingelheim to identify indications related to rare neurological diseases.
The project will leverage Healx’s comprehensive AI-based drug discovery platform, Healnet, and expertise in rare diseases and pharmacology, to identify potential new indications for assets from Boehringer Ingelheim’s pipeline.
Healx will use their data analysis and technological capabilities to assist Boehringer…
Arecor announces positive headline results for the first Phase I clinical trial of AT247, a novel ultra rapid acting formulation of insulin
Favourable pharmacokinetic/pharmacodynamic profile compared to current best in class insulin treatment
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247. In the study, AT247 provided a favourable pharmacokinetic/pharmacodynamic profile compared with NovoRapid® and Fiasp®.…
Cambridge, UK, and Stockholm, Sweden, 03 December 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that it has entered into a partnership with The Human Protein Atlas (HPA). HPA has selected Horizon’s CRISPR-edited knockout cell models to further expand the knowledge available in its Cell Atlas program, to advance our understanding of the genetic drivers of disease. Knockout cell models offer the possibility for an enhanced validation of antibodies based on genetic…
Cambridge, UK, 03 December 2019: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells. The agreement is to generate and optimise antibodies for novel immuno-oncology targets, including access to IONTAS’ proprietary Mammalian Display technology to select antibodies with optimal biophysical properties.
IONTAS’ proprietary technology enables the construction of large libraries of…
Cambridge and London, UK, 03 December 2019: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK independent medical research charity, today announced an extension of their neuroscience-focused ion channel drug discovery collaboration, following the success of the initial twelve-month agreement.
The collaboration is focused on novel selective small molecular modulators of a specific two-pore domain potassium ion channel target, identified as likely to be involved in neurological pathogenesis. Having commenced in January…
Cambridge, UK: Global courier for cell and gene therapy, Biocair, will exhibit at Cell Therapy Manufacturing and Gene Therapy Congress between 3-6 December 2019. Taking place in Amsterdam, Cell Therapy Manufacturing and Gene Therapy Congress brings together key players from the industry to discuss the critical issues facing the development, scale-up and manufacture of cell-based and gene therapies.
Speaking about the logistics surrounding cell and gene therapy, Gert de Gier, Cell and Gene Business Development Director at Biocair, comments that “with cell and gene therapies moving into the…
NEW STATE-OF-THE-ART FACILITY DRAMATICALLY INCREASES CAPACITY FOR CLINICAL TRIALS AND OFFERS CLIENTS FIRST-OF-ITS-KIND CELL PROFILING CAPABILITIES COMBINING EPIGENETICS AND FLOW CYTOMETRY
BERLIN, GERMANY – 27 NOVEMBER 2019 – Precision for Medicine, part of Precision Medicine Group, today announced that they have opened a new 1,600 metre-squared Berlin-based laboratory, for the first time combining its proprietary Epiontis ID™ epigenetic immune-monitoring technology with advanced flow cytometry capabilities, along with a full-service biorepository and cell processing laboratory. Focusing on…